HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Naveen Pemmaraju Selected Research

Prednisone (Sone)

12/2018Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
11/2015Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
9/2014Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Naveen Pemmaraju Research Topics

Disease

78Neoplasms (Cancer)
02/2024 - 10/2013
76Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2023 - 08/2011
29Primary Myelofibrosis (Myelosclerosis)
04/2024 - 09/2014
19Myelodysplastic Syndromes (Myelodysplastic Syndrome)
12/2023 - 01/2015
18Leukemia
10/2023 - 01/2015
17BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
04/2024 - 07/2012
14Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2024 - 12/2014
13Hematologic Neoplasms (Hematological Malignancy)
04/2024 - 01/2017
12Philadelphia Chromosome
06/2023 - 02/2015
10Thrombocytopenia (Thrombopenia)
01/2023 - 01/2018
9Exanthema (Rash)
11/2023 - 11/2015
8Infections
11/2023 - 11/2015
7Anemia
04/2024 - 09/2014
6Splenomegaly
11/2023 - 10/2014
6Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
01/2023 - 10/2013
6Fibrosis (Cirrhosis)
06/2022 - 07/2018
6Residual Neoplasm
01/2021 - 12/2014
5Disease Progression
05/2024 - 01/2018
5Nausea
11/2023 - 02/2015
5Hemorrhage
01/2023 - 01/2015
5Cytopenia
01/2023 - 09/2019
5Capillary Leak Syndrome
12/2021 - 01/2019
5Pathologic Complete Response
07/2020 - 11/2015
4Neutropenia
04/2024 - 01/2021
4Hypertension (High Blood Pressure)
01/2023 - 11/2015
4Pancreatitis
01/2023 - 11/2015
4Pleural Effusion (Pleural Effusions)
11/2022 - 01/2014
4B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
12/2021 - 01/2019
4Acute Promyelocytic Leukemia
01/2021 - 08/2013
3Thrombosis (Thrombus)
11/2023 - 11/2022
3B-Cell Lymphoma (Lymphoma, B Cell)
11/2023 - 01/2019
3Myocardial Infarction
01/2023 - 11/2015
3Hypoalbuminemia
10/2022 - 01/2019
3Edema (Dropsy)
12/2021 - 01/2019
3Fatigue
01/2021 - 01/2018
3Blast Crisis (Blast Phase)
01/2021 - 11/2020
2Polycythemia (Erythrocytosis)
02/2024 - 01/2023
2Peripheral Nervous System Diseases (PNS Diseases)
01/2023 - 02/2015
2Chromosome Aberrations (Chromosome Abnormalities)
11/2022 - 01/2018

Drug/Important Bio-Agent (IBA)

35venetoclaxIBA
04/2024 - 01/2017
19tagraxofuspIBA
04/2024 - 07/2014
17Cytarabine (Cytosar-U)FDA LinkGeneric
11/2023 - 11/2013
17ruxolitinibIBA
01/2023 - 03/2015
14Azacitidine (5 Azacytidine)FDA Link
12/2023 - 01/2015
13DecitabineFDA Link
01/2022 - 09/2015
12Tyrosine Kinase InhibitorsIBA
01/2023 - 07/2012
9Dasatinib (BMS 354825)FDA Link
04/2024 - 07/2012
7Janus Kinase InhibitorsIBA
11/2023 - 01/2015
7Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
11/2023 - 11/2013
7Core Binding Factors (Core-Binding Factor)IBA
01/2023 - 04/2016
7Hemoglobins (Hemoglobin)IBA
01/2023 - 09/2014
6Interleukin-3 Receptors (Interleukin 3 Receptor)IBA
12/2023 - 07/2014
6CladribineFDA LinkGeneric
11/2023 - 01/2014
6ponatinibIBA
10/2023 - 09/2015
6Transaminases (Aminotransferases)IBA
01/2023 - 02/2015
5Proteins (Proteins, Gene)FDA Link
11/2023 - 01/2017
5BilirubinIBA
11/2023 - 02/2015
5Inotuzumab OzogamicinIBA
06/2023 - 01/2018
5fludarabineIBA
01/2023 - 11/2017
5Clofarabine (Clolar)FDA Link
01/2021 - 11/2013
4navitoclaxIBA
11/2023 - 01/2022
4Sorafenib (BAY 43-9006)FDA Link
11/2023 - 01/2019
4ibrutinibIBA
01/2023 - 01/2019
4CytokinesIBA
01/2023 - 10/2019
4NivolumabIBA
01/2023 - 01/2019
4Rituximab (Mabthera)FDA Link
12/2021 - 02/2015
4Vincristine (Oncovin)FDA LinkGeneric
12/2018 - 02/2015
3Chimeric Antigen ReceptorsIBA
01/2023 - 05/2022
3Phosphotransferases (Kinase)IBA
01/2023 - 01/2017
3Gemtuzumab (Mylotarg)FDA Link
11/2022 - 01/2020
3Biomarkers (Surrogate Marker)IBA
06/2022 - 01/2017
3InterferonsIBA
01/2022 - 12/2020
3fms-Like Tyrosine Kinase 3IBA
01/2022 - 07/2014
3Telomerase (Telomerase Reverse Transcriptase)IBA
01/2022 - 10/2019
3Alanine Transaminase (SGPT)IBA
08/2021 - 11/2015
3Lenalidomide (CC 5013)FDA Link
01/2021 - 01/2015
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
10/2019 - 11/2015
3Prednisone (Sone)FDA LinkGeneric
12/2018 - 09/2014
3Janus KinasesIBA
01/2017 - 01/2015
3Imatinib Mesylate (Gleevec)FDA Link
11/2016 - 07/2012
3nilotinibFDA Link
11/2016 - 07/2012
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
04/2024 - 08/2013
2Interleukin-3 (Interleukin 3)IBA
12/2023 - 10/2019
2Diphtheria ToxinIBA
12/2023 - 10/2019
2Hydroxyurea (Hydrea)FDA LinkGeneric
11/2023 - 01/2023
2CPX-351IBA
11/2023 - 11/2020
2PLX51107IBA
11/2023 - 01/2022
2Apoptosis Regulatory ProteinsIBA
10/2023 - 01/2019
2blinatumomabIBA
06/2023 - 01/2019
2NucleophosminIBA
01/2023 - 08/2013
2Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
11/2022 - 01/2021
211- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA
11/2022 - 01/2022

Therapy/Procedure

87Therapeutics
11/2023 - 07/2012
38Drug Therapy (Chemotherapy)
05/2024 - 08/2011
6Immunotherapy
05/2022 - 01/2017
5Stem Cell Transplantation
01/2023 - 05/2015
4Induction Chemotherapy
01/2022 - 01/2016
3Cell Transplantation
01/2023 - 03/2019
3Drug Tapering
01/2020 - 01/2018
2Hematopoietic Stem Cell Transplantation
01/2023 - 08/2013